Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats - PubMed (original) (raw)
Comparative Study
. 2006 Jun;186(2):209-17.
doi: 10.1007/s00213-006-0369-4. Epub 2006 Apr 4.
Affiliations
- PMID: 16586089
- DOI: 10.1007/s00213-006-0369-4
Comparative Study
Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats
Han-Ting Zhang et al. Psychopharmacology (Berl). 2006 Jun.
Abstract
Rationale: Phosphodiesterase-4 (PDE4) has two conformation states based on rolipram binding, the high-affinity rolipram binding state (HARBS) and the low-affinity rolipram binding state (LARBS); their functions remain to be fully explained.
Objective: Experiments were carried out to determine the roles of the HARBS and LARBS in the mediation of antidepressant-like effects on behavior.
Materials and methods: Two animal models sensitive to antidepressant drugs, the forced-swim test (FST), and the differential-reinforcement-of-low-rate (DRL) 72-s operant schedule, were used to examine the antidepressant-like effects of rolipram, CDP840, and piclamilast, PDE4 inhibitors that interact differentially with the HARBS and LARBS, and MEM1018 and MEM1091, two novel PDE4 inhibitors. Drug discrimination vs rolipram and rolipram competition binding assays also were carried out.
Results: In the FST, rolipram and piclamilast, both at 0.1 mg/kg, produced an antidepressant-like effect, i.e., reduced immobility and increased swimming, whereas, 1 mg/kg of CDP840 or 0.5 mg/kg of MEM1018 or MEM1091 was required to produce a similar effect. Consistent with this, only rolipram and piclamilast produced antidepressant-like effects in rats under the DRL schedule of reinforcement, as evidenced by decreased response rates and increased reinforcement rates. In addition, in rats trained to discriminate rolipram from its vehicle, only rolipram and piclamilast substituted. Finally, [(3)H]rolipram and [(3)H]piclamilast binding analysis revealed that CDP840 and the two novel PDE4 inhibitors MEM1018 and MEM1091 exhibited a lower affinity for the HARBS than did rolipram.
Conclusion: These results suggest that the HARBS of PDE4 is the primary conformation important for antidepressant-like effects on behavior.
Similar articles
- Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]piclamilast and [3H]rolipram.
Zhao Y, Zhang HT, O'Donnell JM. Zhao Y, et al. J Pharmacol Exp Ther. 2003 May;305(2):565-72. doi: 10.1124/jpet.102.47407. J Pharmacol Exp Ther. 2003. PMID: 12704225 - Interaction between the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDE inhibitor rolipram in rats.
Zhang HT, Huang Y, Mishler K, Roerig SC, O'Donnell JM. Zhang HT, et al. Psychopharmacology (Berl). 2005 Oct;182(1):104-15. doi: 10.1007/s00213-005-0055-y. Epub 2005 Sep 29. Psychopharmacology (Berl). 2005. PMID: 16010541 - Effects of the novel PDE4 inhibitors MEM1018 and MEM1091 on memory in the radial-arm maze and inhibitory avoidance tests in rats.
Zhang HT, Huang Y, Suvarna NU, Deng C, Crissman AM, Hopper AT, De Vivo M, Rose GM, O'Donnell JM. Zhang HT, et al. Psychopharmacology (Berl). 2005 May;179(3):613-9. doi: 10.1007/s00213-004-2085-2. Epub 2005 Jan 26. Psychopharmacology (Berl). 2005. PMID: 15672274 - Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases.
Souness JE, Rao S. Souness JE, et al. Cell Signal. 1997 May-Jun;9(3-4):227-36. doi: 10.1016/s0898-6568(96)00173-8. Cell Signal. 1997. PMID: 9218122 Review. - Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4).
O'Donnell JM, Zhang HT. O'Donnell JM, et al. Trends Pharmacol Sci. 2004 Mar;25(3):158-63. doi: 10.1016/j.tips.2004.01.003. Trends Pharmacol Sci. 2004. PMID: 15019272 Review. No abstract available.
Cited by
- Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases.
Omar F, Findlay JE, Carfray G, Allcock RW, Jiang Z, Moore C, Muir AL, Lannoy M, Fertig BA, Mai D, Day JP, Bolger G, Baillie GS, Schwiebert E, Klussmann E, Pyne NJ, Ong ACM, Bowers K, Adam JM, Adams DR, Houslay MD, Henderson DJP. Omar F, et al. Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13320-13329. doi: 10.1073/pnas.1822113116. Epub 2019 Jun 17. Proc Natl Acad Sci U S A. 2019. PMID: 31209056 Free PMC article. - Phosphodiesterase 4 inhibitors enhance sexual pleasure-seeking activity in rodents.
Yuan P, Tragon T, Xia M, Leclair CA, Skoumbourdis AP, Zheng W, Thomas CJ, Huang R, Austin CP, Chen G, Guitart X. Yuan P, et al. Pharmacol Biochem Behav. 2011 May;98(3):349-55. doi: 10.1016/j.pbb.2011.02.001. Epub 2011 Feb 4. Pharmacol Biochem Behav. 2011. PMID: 21296104 Free PMC article. - Clinical Implication of Phosphodiesterase-4-Inhibition.
Schick MA, Schlegel N. Schick MA, et al. Int J Mol Sci. 2022 Jan 21;23(3):1209. doi: 10.3390/ijms23031209. Int J Mol Sci. 2022. PMID: 35163131 Free PMC article. Review. - A new model of Pde4d deficiency: genetic knock-down of PDE4D enzyme in rats produces an antidepressant phenotype without spatial cognitive effects.
Schaefer TL, Braun AA, Amos-Kroohs RM, Williams MT, Ostertag E, Vorhees CV. Schaefer TL, et al. Genes Brain Behav. 2012 Jul;11(5):614-22. doi: 10.1111/j.1601-183X.2012.00796.x. Epub 2012 May 8. Genes Brain Behav. 2012. PMID: 22487514 Free PMC article. - PDE4D: A Multipurpose Pharmacological Target.
Lusardi M, Rapetti F, Spallarossa A, Brullo C. Lusardi M, et al. Int J Mol Sci. 2024 Jul 24;25(15):8052. doi: 10.3390/ijms25158052. Int J Mol Sci. 2024. PMID: 39125619 Free PMC article. Review.
References
- Psychopharmacology (Berl). 2003 Oct;170(1):102-7 - PubMed
- Eur J Pharmacol. 1986 Aug 7;127(1-2):105-15 - PubMed
- Psychopharmacology (Berl). 2005 May;179(3):613-9 - PubMed
- Nihon Yakurigaku Zasshi. 1989 Jul;94(1):81-9 - PubMed
- Psychopharmacology (Berl). 1990;102(1):17-20 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous